Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer by Johnny R. Ramroop, Mark N. Stein, Mark N. Stein, Justin M. Drake, Justin M. Drake, Justin M. Drake

Get full text

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer by Mark N Stein, Neal Patel, Alexander Bershadskiy, Alisa Sokoloff, Eric A Singer

Get full text

Identification of the DNA repair defects in a case of Dubowitz syndrome. by Jingyin Yue, Huimei Lu, Shijie Lan, Jingmei Liu, Mark N Stein, Bruce G Haffty, Zhiyuan Shen

Get full text

Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach by Brian M. Shinder, Kevin Rhee, Douglas Farrell, Nicholas J. Farber, Mark N. Stein, Thomas L. Jang, Eric A. Singer

Get full text

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era by Isaac E. Kim, Thomas L. Jang, Sinae Kim, David Y. Lee, Daniel D. Kim, Eric A. Singer, Saum Ghodoussipour, Mark N. Stein, Monish Aron, Marc A. Dall’Era, Isaac Yi Kim

Get full text

764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with... by Benjamin Thompson, Li Yao, Yana G Najjar, Siwen Hu-Lieskovan, Raphael Clynes, Bartosz Chmielowski, Mark N Stein, Sarina A Piha-Paul, Patricia McGovern, Judy S Wang, Benjamin Garmezy, Manojkumar Bupathi, Jitendra Kanodia

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy by Julie N. Graff, Julie N. Graff, Mark N. Stein, Rishi Surana, Luai Al Rabadi, Luai Al Rabadi, Eric Liu, Lawrence Fong, Shawna Bailey, Emile Latour, Timothy A. Newby, Amy E. Moran, Tomasz M. Beer

Get full text

665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress by Neal Shore, Robert Dreicer, Matthew Zibelman, Mark N Stein, Ralph J Hauke, Russell Pachynski, Bethan Jones, Jessica Hawley, Charlotte Davis, Katie Anderson, Antonella Vardeu, Margaret A Marshall, Vicky Wheeler, Sarah Sebastian, Kevin Kayvan Zarrabi, Brian Miles, Jennifer Bendall

Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer by Xiang‐Lin Tan, Jian‐Yu E, Yong Lin, Timothy R. Rebbeck, Shou‐En Lu, Mingyi Shang, William K. Kelly, Anthony D'Amico, Mark N. Stein, Lanjing Zhang, Thomas L. Jang, Isaac Yi Kim, Kitaw Demissie, Anna Ferrari, Grace Lu‐Yao

Get full text

Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer by Bertram E. Yuh, Young Suk Kwon, Brian M. Shinder, Eric A. Singer, Thomas L. Jang, Sinae Kim, Mark N. Stein, Tina Mayer, Anna Ferrari, Nara Lee, Rahul R. Parikh, Nora Ruel, Wun-Jae Kim, Shigeo Horie, Seok-Soo Byun, Thomas E. Ahlering, Isaac Yi Kim

Get full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. by Bert H O'Neil, John M Wallmark, David Lorente, Elena Elez, Judith Raimbourg, Carlos Gomez-Roca, Samuel Ejadi, Sarina A Piha-Paul, Mark N Stein, Albiruni R Abdul Razak, Katia Dotti, Armando Santoro, Roger B Cohen, Marlena Gould, Sanatan Saraf, Karen Stein, Sae-Won Han

Get full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma by Daniel P. Petrylak, Lawrence Fong, Charles G. Drake, Mark N. Stein, Douglas G. McNeel, Ravi A. Madan, James L. Gulley, Neil H. Bander, Tomasz M. Beer, Stacey Harrelson, Philip W. Kantoff, William K. Oh, David J. Peace, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Johannes Vieweg

Get full text

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy by Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher

Get full text

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration by Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza

Get full text